$3.59
1.64%
Nasdaq, Sep 24, 04:00 pm EDT.
ISIN
US0977021049
Symbol
BOLT

Bolt Biotherapeutics Inc Stock price

$3.59
-0.15 4.01% 1M
-0.70 16.32% 6M
-1.88 34.35% YTD
-2.18 37.78% 1Y
-17.01 82.57% 3Y
-254.01 98.61% 5Y
-639.41 99.44% 10Y
-639.41 99.44% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
-0.06 1.64%
ISIN
US0977021049
Symbol
BOLT
Industry

Is Bolt Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$6.9m
Enterprise Value
$-10.7m
Net debt
positive
Cash
$17.6m
Shares outstanding
1.9m
Valuation (TTM | estimate)
P/E
negative
P/S
1.5 | 33.9
EV/Sales
negative | negative
EV/FCF
0.3
P/B
0.6
Financial Health
Equity Ratio
46.7%
Return on Equity
-125.9%
ROCE
-87.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.7m | $204.0k
EBITDA
$-27.6m
EBIT
$-28.5m
Net Income
$-28.7m
Free Cash Flow
$-31.5m
Growth (TTM | estimate)
Revenue
12.7% | -97.4%
EBITDA
46.8%
EBIT
46.7%
Net Income
43.3%
Free Cash Flow
38.6%
Margin
Gross
-
EBITDA
-586.3%
EBIT
-605.9%
Net
-611.5%
Free Cash Flow
-671.0%
More
EPS
$-17.0
FCF per Share
$-16.3
Short interest
0.8%
Employees
23
Rev per Employee
$330.0k

Bolt Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Bolt Biotherapeutics Inc forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a Bolt Biotherapeutics Inc forecast:

Buy
70%
Hold
30%

Financial data from Bolt Biotherapeutics Inc

Jun '26
+/-
%
4.70 4.70
13% 13%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
23% 23%
248%
- Research and Development Expense 22 22
49% 49%
457%
-28 -28
47% 47%
-586%
- Depreciation and Amortization 0.92 0.92
43% 43%
20%
EBIT (Operating Income) EBIT -28 -28
47% 47%
-606%
Net Profit -29 -29
43% 43%
-611%

In millions USD.

Don't miss a Thing! We will send you all news about Bolt Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bolt Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
●
about one month ago
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company develo...
Neutral
Accesswire
●
4 months ago
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May 13, 2026, the letter of intent dated October 23, 2025, and the definitive option agreement dated May 12, 2026, as amended (the "Option Agreement"), with Max Iron Brazil Ltd. ("MaxIron"), an entity ...
Neutral
GlobeNewsWire
●
5 months ago
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Company Profile

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.

Head office United States
CEO Mr. Quinn
Employees 23
Founded 2015
Website boltbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today